Multi-omics analysis for potential inflammation-related genes involved in tumour immune evasion via extended application of epigenetic data.
ATAC-seq
PD-L1
STAT2
epigenetics
immune checkpoint therapy
immune evasion
Journal
Open biology
ISSN: 2046-2441
Titre abrégé: Open Biol
Pays: England
ID NLM: 101580419
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
entrez:
10
8
2022
pubmed:
11
8
2022
medline:
12
8
2022
Statut:
ppublish
Résumé
Accumulating evidence suggests that inflammation-related genes may play key roles in tumour immune evasion. Programmed cell death ligand 1 (PD-L1) is an important immune checkpoint involved in mediating anti-tumour immunity. We performed multi-omics analysis to explore key inflammation-related genes affecting the transcriptional regulation of PD-L1 expression. The open chromatin region of the PD-L1 promoter was mapped using the assay for transposase-accessible chromatin using sequencing (ATAC-seq) profiles. Correlation analysis of epigenetic data (ATAC-seq) and transcriptome data (RNA-seq) were performed to identify inflammation-related transcription factors (TFs) whose expression levels were correlated with the chromatin accessibility of the PD-L1 promoter. Chromatin immunoprecipitation sequencing (ChIP-seq) profiles were used to confirm the physical binding of the TF STAT2 and the predicted binding regions. We also confirmed the results of the bioinformatics analysis with cell experiments. We identified chr9 : 5449463-5449962 and chr9 : 5450250-5450749 as reproducible open chromatin regions in the PD-L1 promoter. Moreover, we observed a correlation between STAT2 expression and the accessibility of the aforementioned regions. Furthermore, we confirmed its physical binding through ChIP-seq profiles and demonstrated the regulation of PD-L1 by STAT2 overexpression
Identifiants
pubmed: 35946310
doi: 10.1098/rsob.210375
pmc: PMC9364145
doi:
Substances chimiques
B7-H1 Antigen
0
Chromatin
0
Banques de données
figshare
['10.6084/m9.figshare.c.6139248']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
210375Références
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Front Immunol. 2020 Nov 25;11:584626
pubmed: 33324403
Front Immunol. 2018 Nov 13;9:2542
pubmed: 30483250
Immunity. 2018 Mar 20;48(3):434-452
pubmed: 29562194
Nat Rev Cancer. 2009 Nov;9(11):798-809
pubmed: 19851315
Immunity. 2020 Jan 14;52(1):36-54
pubmed: 31940272
J Clin Invest. 2003 Aug;112(4):535-43
pubmed: 12925694
Immunity. 2012 Apr 20;36(4):503-14
pubmed: 22520844
Front Cell Dev Biol. 2021 Jul 02;9:662707
pubmed: 34277610
Science. 2018 Oct 26;362(6413):
pubmed: 30361341
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Nucleic Acids Res. 2019 Nov 18;47(20):10580-10596
pubmed: 31584093
Nucleic Acids Res. 2020 Jul 2;48(W1):W509-W514
pubmed: 32442275
Genome Biol. 2011 Aug 22;12(8):R83
pubmed: 21859476
Front Immunol. 2022 Jan 03;12:741634
pubmed: 35046932
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102
pubmed: 28407145
Nat Rev Clin Oncol. 2021 Jun;18(6):345-362
pubmed: 33580222
Bioinformatics. 2017 Oct 01;33(19):3088-3090
pubmed: 28575171
Science. 2017 Aug 18;357(6352):
pubmed: 28818916
Semin Cancer Biol. 2020 Feb;60:41-56
pubmed: 31605750
Bioinformatics. 2015 Jul 15;31(14):2382-3
pubmed: 25765347
Cell Res. 2020 Aug;30(8):660-669
pubmed: 32467592
Lancet Oncol. 2017 Sep;18(9):1182-1191
pubmed: 28734759
Int J Cancer. 2015 Jan 1;136(1):117-26
pubmed: 24895110
Cell Rep. 2017 May 9;19(6):1189-1201
pubmed: 28494868
Nucleic Acids Res. 2018 Jan 4;46(D1):D956-D963
pubmed: 29136207
Cancer Prev Res (Phila). 2010 Apr;3(4):495-504
pubmed: 20233899
Front Oncol. 2021 Jan 05;10:609940
pubmed: 33469515
Cell. 2018 Feb 8;172(4):650-665
pubmed: 29425488